Eventide Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Eventide Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-61,714	Closed	-$2.27M	–	125
2019 Q3	$2.27M	Hold	61,714	–	–	0.08%	94
2019 Q2	$3.41M	Hold	61,714	–	–	0.1%	89
2019 Q1	$3.75M	Buy	61,714 +28,914	+88%	+$1.86M	0.13%	93
2018 Q4	$1.94M	Hold	32,800	–	–	0.09%	107
2018 Q3	$2.65M	Hold	32,800	–	–	0.1%	111
2018 Q2	$2.87M	Buy	+32,800	New	+$5.75M	0.12%	105

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eventide Asset Management's GYRE Position: Q4 2019 in Review

Eventide Asset Management sold out of Gyre Therapeutics (GYRE) in Q4 2019, closing a stake of 61,714 shares — an estimated $2.27M sold.

Eventide Asset Management first reported a position in GYRE in Q2 2018 and held it in 6 quarters. The position peaked at $3.75M in Q1 2019. 46 funds tracked by Wall St. Rank hold GYRE as of Q4 2019.

Eventide Asset Management reported no remaining Gyre Therapeutics position as of Q4 2019 after selling out during the quarter.
Eventide Asset Management sold 61,714 Gyre Therapeutics shares in Q4 2019, an estimated $2.27M.
Eventide Asset Management first reported a position in Gyre Therapeutics in Q2 2018 and held it in 6 quarters.
Eventide Asset Management's Gyre Therapeutics position peaked at $3.75M in Q1 2019.
46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2019.

Based on Eventide Asset Management's 13F filing for Q4 2019, filed 29 Jan 2020.